Availability of anti-Parkinsonian drugs in Thailand
Objective: To determine the availability of two categories of anti-PD drugs in each level of healthcare facilities and region in Thailand. Background: Anti-Parkinsonian (PD) drugs…Slow Release Fixed Dose Combination of Low Doses Pramipexole and Rasagiline (P2B001) for the Treatment of Early Parkinson’s Disease (PD).
Objective: Evaluation of the efficacy and safety of a slow release low dose combination of pramipexole (PPX) and rasagiline (RAS) (P2B001) in a prospective double-blind…Ambulatory movement measurement in evaluating deep brain stimulation effect in patients with advanced Parkinson’s disease
Objective: To assess the use of the Parkinson's Kinetigraph™ (PKG™) in evaluating the effect of deep brain stimulation (DBS) in patients with advanced Parkinson's disease (PD). Background: Assessment of the effect of DBS on bradykinesia…The landscape of interventional trials in Parkinson disease: A 10-year review of ClinicalTrials.gov between 2006 and 2016
Objective: To review the scope of interventional trials for Parkinson disease registered on clinicaltrials.gov in the past 10 years. Background: Parkinson disease (PD) is a broad chronic condition…Gait Asymmetry and Parkinson’s Disease
Objective: To evaluate gait asymmetry using velocity-dependent gait analysis and compare to UPDRS asymmetries. Background: Motor impairment, including gait impairment, in patients with Parkinson’s disease…Caffeine as a Treatment for Parkinson’s Disease: A Randomized Controlled Trial (CafePD)
Objective: To assess the effects of caffeine on patients with Parkinson's disease. Background: Multiple studies have linked use of caffeine, an adenosine antagonist, to a…Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson’s disease: A single-dose study
Objective: Evaluate the efficacy and safety of IPX203 vs. immediate-release (IR) carbidopa-levodopa (CD-LD) and vs. extended-release (ER) CD-LD (IPX066, RYTARY®) in patients with advanced Parkinson’s…Effect of food on Opicapone pharmacokinetics and pharmacodynamics
Objective: To characterize the effect of food on the pharmacokinetics (PK) and pharmacodynamics (PD) of opicapone (OPC) after single and repeated doses. Background: OPC, a…Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson’s disease
Objective: To employ a combination of elemental concentrations in the cerebrospinal fluid (CSF) to identify a diagnostic biomarker profile differentiating patients with idiopathic Parkinson´s disease…Relationship between non-motor symptoms and dopamine transporter activity in Parkinson’ s disease
Objective: We investigated whether dopamine transporter single-photon emission computed tomography (DAT-SPECT) binding correlates to non-motor symptoms in patients with Parkinson’s disease (PD). Background: DAT-SPECT binding…
- « Previous Page
- 1
- …
- 54
- 55
- 56
- 57
- 58
- …
- 155
- Next Page »